Free Trial
→ Mysterious drone activity triggers massive 1,366% surge (From Insiders Exposed) (Ad)

10 Best Penny Stocks to Buy Now - 10 of 10

Slide 10
Back to 9
Next Slideshow
 
Back to 9
Next Slideshow
 

Nektar Therapeutics (NASDAQ:NKTR)

Number of Upgrades from Top-Ranked Analysts
3 (in the last 90 days)
Consensus Rating
Moderate Buy
Rating Score
2.7
Ratings Breakdown
4 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$4.10 (355.3% Upside)

About Nektar Therapeutics

Nektar Therapeutics logoNektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
12/10/2024HC WainwrightInitiated CoverageBuy$6.50
11/4/2024Piper SandlerInitiated CoverageOverweight$7.00
9/30/2024BTIG ResearchReiterated RatingBuy$4.00
6/28/2024Rodman & RenshawInitiated CoverageBuy$2.00
3/6/2024Jefferies Financial GroupBoost Price TargetHold ➝ Hold$0.50 ➝ $1.00
3/5/2024William BlairReiterated RatingMarket Perform
11/20/2023JPMorgan Chase & Co.Reiterated RatingUnderweight
11/9/2023TD CowenUpgradeMarket Perform ➝ Outperform
8/7/2023MizuhoReiterated RatingNeutral$6.00
5/10/2023Jefferies Financial GroupUpgradeUnderperform ➝ Hold$1.50 ➝ $1.00

 

While no one can say for sure that these will be the ten best penny stocks next year, Wall Street's top analysts are giving them high price targets, "buy" ratings and are telling their clients to acquire shares.

More Investing Slideshows:

Slide 10
Back to 9
Next Slideshow
 

Forced out of retirement by these trades (Ad)

You know, I never really intended to get in front of a camera and tell folks about a new market paradigm that I discovered. Even though I have a bright and shiny “resume,” I thought I’d left investing behind forever. And I was more than happy to be a stay-at-home dad… But then I discovered Gamma Pockets… and everything changed

Make sure to check out Gamma Pockets HERE while it’s still widely available 

More From MarketBeat
Amazon coin set to soar 25X – starting December 16th?
This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...
True Market Insiders | Sponsored
Betting on a Santa Claus Rally? Consider These 7 Risk-On Stocks
We're getting into the time of year when people start talking about a Santa Claus rally. Specifically, that's ...
MarketBeat
$2 Trillion Disappears Because of Fed's Secretive New Move
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...
Stansberry Research | Sponsored
7 Best Chinese Stocks to Own Before the Bubble Bursts
The geopolitical relationship between the United States and China is volatile and complicated. But the importa...
MarketBeat
Did You See Trump’s Bombshell Exec. Order 001?
Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."
Banyan Hill Publishing | Sponsored
7 Mid-Cap Stocks That Are Ready to Rally
One of the primary issues moving markets in 2024 is the direction of interest rates. Specifically, when will t...
MarketBeat